COX-2 overexpression as a biomarker of early cervical carcinogenesis

A pilot study

J. Salvador Saldivar, David Lopez, Rebecca A. Feldman, Reena Tharappel-Jacob, Antonio de la Rosa, Daniel Terreros, William S. Baldwin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background.: Recent studies have demonstrated that cyclooxygenase-2 (COX-2) expression is up-regulated in a number of cancers. Selective inhibition of COX-2 offers a potential pharmacological strategy for cancer prevention. The COX-2 isoform is induced in response to inflammatory factors and is expressed in premalignant lesions, including cervical tissues. Few studies have investigated COX-2 expression as a biomarker for early cervical carcinogenesis. In this preliminary study, we assessed the variability of COX-2 overexpression in cervical premalignant lesions. Methods.: Fifty-two patients were recruited and consented. Paired abnormal and control (normal) cervical biopsies were obtained and evaluated for high-risk human papillomavirus (HPV), inflammation, histopathological diagnosis, and COX-2 protein concentration by ELISA. Paired Student's t-test and general linear regression models were used to compare mean COX-2 protein concentrations among biopsy samples and selected risk variables. Results.: Forty-seven of fifty-two paired biopsies were evaluated. COX-2 protein concentrations were 4.9-fold greater in abnormal biopsies (CIN 1 and CIN 2) than normal biopsies. COX-2 was also significantly increased in inflammation-positive biopsies. No significant association was found between COX-2 levels and HPV high-risk positivity, age, parity, STI history, or hormonal contraceptive use, but the sample size was small. Conclusions.: These results suggest that COX-2 induction begins in the premalignant phase of cervical carcinogenesis and is correlated with inflammation. A trial using a much larger number of specimens will allow further development of our understanding of COX-2 as a biomarker for use in chemoprevention trials.

Original languageEnglish (US)
JournalGynecologic Oncology
Volume107
Issue number1 SUPPL.
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Carcinogenesis
Biomarkers
Biopsy
Inflammation
Linear Models
Proteins
Chemoprevention
Sexually Transmitted Diseases
Contraceptive Agents
Parity
Sample Size
Neoplasms
Protein Isoforms
Enzyme-Linked Immunosorbent Assay
Pharmacology
Students

Keywords

  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • COX-2
  • Inflammation

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Saldivar, J. S., Lopez, D., Feldman, R. A., Tharappel-Jacob, R., de la Rosa, A., Terreros, D., & Baldwin, W. S. (2007). COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study. Gynecologic Oncology, 107(1 SUPPL.). https://doi.org/10.1016/j.ygyno.2007.07.023

COX-2 overexpression as a biomarker of early cervical carcinogenesis : A pilot study. / Saldivar, J. Salvador; Lopez, David; Feldman, Rebecca A.; Tharappel-Jacob, Reena; de la Rosa, Antonio; Terreros, Daniel; Baldwin, William S.

In: Gynecologic Oncology, Vol. 107, No. 1 SUPPL., 01.10.2007.

Research output: Contribution to journalArticle

Saldivar, JS, Lopez, D, Feldman, RA, Tharappel-Jacob, R, de la Rosa, A, Terreros, D & Baldwin, WS 2007, 'COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study', Gynecologic Oncology, vol. 107, no. 1 SUPPL.. https://doi.org/10.1016/j.ygyno.2007.07.023
Saldivar JS, Lopez D, Feldman RA, Tharappel-Jacob R, de la Rosa A, Terreros D et al. COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study. Gynecologic Oncology. 2007 Oct 1;107(1 SUPPL.). https://doi.org/10.1016/j.ygyno.2007.07.023
Saldivar, J. Salvador ; Lopez, David ; Feldman, Rebecca A. ; Tharappel-Jacob, Reena ; de la Rosa, Antonio ; Terreros, Daniel ; Baldwin, William S. / COX-2 overexpression as a biomarker of early cervical carcinogenesis : A pilot study. In: Gynecologic Oncology. 2007 ; Vol. 107, No. 1 SUPPL.
@article{6e65bc2ccec147bfb4c8a60cc7cc6464,
title = "COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study",
abstract = "Background.: Recent studies have demonstrated that cyclooxygenase-2 (COX-2) expression is up-regulated in a number of cancers. Selective inhibition of COX-2 offers a potential pharmacological strategy for cancer prevention. The COX-2 isoform is induced in response to inflammatory factors and is expressed in premalignant lesions, including cervical tissues. Few studies have investigated COX-2 expression as a biomarker for early cervical carcinogenesis. In this preliminary study, we assessed the variability of COX-2 overexpression in cervical premalignant lesions. Methods.: Fifty-two patients were recruited and consented. Paired abnormal and control (normal) cervical biopsies were obtained and evaluated for high-risk human papillomavirus (HPV), inflammation, histopathological diagnosis, and COX-2 protein concentration by ELISA. Paired Student's t-test and general linear regression models were used to compare mean COX-2 protein concentrations among biopsy samples and selected risk variables. Results.: Forty-seven of fifty-two paired biopsies were evaluated. COX-2 protein concentrations were 4.9-fold greater in abnormal biopsies (CIN 1 and CIN 2) than normal biopsies. COX-2 was also significantly increased in inflammation-positive biopsies. No significant association was found between COX-2 levels and HPV high-risk positivity, age, parity, STI history, or hormonal contraceptive use, but the sample size was small. Conclusions.: These results suggest that COX-2 induction begins in the premalignant phase of cervical carcinogenesis and is correlated with inflammation. A trial using a much larger number of specimens will allow further development of our understanding of COX-2 as a biomarker for use in chemoprevention trials.",
keywords = "Cervical cancer, Cervical intraepithelial neoplasia, COX-2, Inflammation",
author = "Saldivar, {J. Salvador} and David Lopez and Feldman, {Rebecca A.} and Reena Tharappel-Jacob and {de la Rosa}, Antonio and Daniel Terreros and Baldwin, {William S.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.ygyno.2007.07.023",
language = "English (US)",
volume = "107",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - COX-2 overexpression as a biomarker of early cervical carcinogenesis

T2 - A pilot study

AU - Saldivar, J. Salvador

AU - Lopez, David

AU - Feldman, Rebecca A.

AU - Tharappel-Jacob, Reena

AU - de la Rosa, Antonio

AU - Terreros, Daniel

AU - Baldwin, William S.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Background.: Recent studies have demonstrated that cyclooxygenase-2 (COX-2) expression is up-regulated in a number of cancers. Selective inhibition of COX-2 offers a potential pharmacological strategy for cancer prevention. The COX-2 isoform is induced in response to inflammatory factors and is expressed in premalignant lesions, including cervical tissues. Few studies have investigated COX-2 expression as a biomarker for early cervical carcinogenesis. In this preliminary study, we assessed the variability of COX-2 overexpression in cervical premalignant lesions. Methods.: Fifty-two patients were recruited and consented. Paired abnormal and control (normal) cervical biopsies were obtained and evaluated for high-risk human papillomavirus (HPV), inflammation, histopathological diagnosis, and COX-2 protein concentration by ELISA. Paired Student's t-test and general linear regression models were used to compare mean COX-2 protein concentrations among biopsy samples and selected risk variables. Results.: Forty-seven of fifty-two paired biopsies were evaluated. COX-2 protein concentrations were 4.9-fold greater in abnormal biopsies (CIN 1 and CIN 2) than normal biopsies. COX-2 was also significantly increased in inflammation-positive biopsies. No significant association was found between COX-2 levels and HPV high-risk positivity, age, parity, STI history, or hormonal contraceptive use, but the sample size was small. Conclusions.: These results suggest that COX-2 induction begins in the premalignant phase of cervical carcinogenesis and is correlated with inflammation. A trial using a much larger number of specimens will allow further development of our understanding of COX-2 as a biomarker for use in chemoprevention trials.

AB - Background.: Recent studies have demonstrated that cyclooxygenase-2 (COX-2) expression is up-regulated in a number of cancers. Selective inhibition of COX-2 offers a potential pharmacological strategy for cancer prevention. The COX-2 isoform is induced in response to inflammatory factors and is expressed in premalignant lesions, including cervical tissues. Few studies have investigated COX-2 expression as a biomarker for early cervical carcinogenesis. In this preliminary study, we assessed the variability of COX-2 overexpression in cervical premalignant lesions. Methods.: Fifty-two patients were recruited and consented. Paired abnormal and control (normal) cervical biopsies were obtained and evaluated for high-risk human papillomavirus (HPV), inflammation, histopathological diagnosis, and COX-2 protein concentration by ELISA. Paired Student's t-test and general linear regression models were used to compare mean COX-2 protein concentrations among biopsy samples and selected risk variables. Results.: Forty-seven of fifty-two paired biopsies were evaluated. COX-2 protein concentrations were 4.9-fold greater in abnormal biopsies (CIN 1 and CIN 2) than normal biopsies. COX-2 was also significantly increased in inflammation-positive biopsies. No significant association was found between COX-2 levels and HPV high-risk positivity, age, parity, STI history, or hormonal contraceptive use, but the sample size was small. Conclusions.: These results suggest that COX-2 induction begins in the premalignant phase of cervical carcinogenesis and is correlated with inflammation. A trial using a much larger number of specimens will allow further development of our understanding of COX-2 as a biomarker for use in chemoprevention trials.

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - COX-2

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=34748923100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748923100&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.07.023

DO - 10.1016/j.ygyno.2007.07.023

M3 - Article

VL - 107

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1 SUPPL.

ER -